Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bananin
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
**bananin** is an experimental small-molecule antiviral compound and the prototype member of the bananins, a trioxa-adamantane-triol class derived from an adamantane-like scaffold linked to a pyridoxal-related moiety. It was reported as an inhibitor of the SARS coronavirus helicase, with activity against the ATPase and helicase functions of the viral nsp13 enzyme and corresponding inhibition of SARS-CoV replication in cell-based research systems. The compound appears to have remained a preclinical research agent rather than an approved or clinically developed medicine, and published work has focused mainly on SARS-CoV and broader exploratory anti-RNA-virus research.
- Other names
- BN
02
Targets
NSP13 (SARS-CoV-2 helicase)
Beyond the preview
Go deeper on bananin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bananin.